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Abstract
Adrenal “incidentalomas” refer to a group of adrenal masses initially discovered during 
cross-sectional imaging obtained for other clinical reasons. The majority of incidentalo-
mas are benign nonfunctional adrenal adenomas and can be safely managed expectantly. 
A subset of adrenal incidentalomas, however, are functional and/or malignant, and these 
lesions most often require adrenalectomy. The following chapter outlines the differential 
diagnosis, the different imaging modalities and features, as well as biochemical evalua-
tion of adrenal incidentalomas.
Keywords: adrenal, mass, function
1. Introduction
An adrenal incidentaloma refers to an adrenal mass that is incidentally found on imaging 
studies not intended initially to assess the adrenal glands. This term does not include adrenal 
masses that were discovered in patients with a genetic predisposition to develop adrenal 
tumors nor in patients with extra-adrenal malignancies discovered on imaging studies for 
cancer staging purposes.
The frequency of adrenal incidentalomas varies in the literature. Autopsy studies report an 
incidence of adrenal incidentalomas ranging from 1 to 9% [1]. Frequency of adrenal inci-
dentalomas reported in the radiology literature varies according to imaging modality. With 
computed tomography (CT) scans and magnetic resonance imaging (MRI), incidence of these 
adrenal tumors ranges from 0.3 to 7%, whereas prevalence of adrenal incidentalomas from 
ultrasound studies reaches 0.4–2% [2]. The discovery of adrenal incidentalomas increases 
with age where prevalence in patients <30 years of age is <1%, but 7% in patients >70 years of 
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age. Furthermore, patients with obesity, diabetes, and hypertension are more likely to have 
an incidental adrenal masses [3].
2. Etiology
Adrenal incidentalomas are categorized by malignant potential and functionality. These 
categorizations are utilized to determine the necessity for surgical resection. Most adrenal 
incidentalomas are benign nonfunctioning adenomas (71%), but such lesions may represent 
lipomas, cysts, myelolipomas, hamartomas, ganglioneuromas, teratomas, neurofibromas, 
leiomyomatosis, hematomas, or infections. Malignant adrenal tumors are rare, consisting of 
primary adrenocortical carcinoma (4%) and metastases (2%) from other regions. Radiographic 
features and tumor size are used to predict the risk of malignancy.
Approximately 20% of functional adrenal incidentalomas, which occur less frequently than 
benign nonfunctional tumors, are found incidentally during imaging. Similarly, symptoms 
typical of adrenal hypersecretion are common in patients found to have hormonal syndromes, 
but functional adrenal incidentalomas are rarely symptomatic. Functional adrenal tumors 
include those that hypersecrete cortisol (8%), catecholamines (6%), and aldosterone (2%).
This chapter focuses on the comprehensive evaluation of incidental adrenal tumors (Figure 1). 
Classic imaging findings, clinical presentation, and surgical indications will also be outlined 
in detail.
2.1. Imaging characteristics
Although adrenal incidentalomas are found fortuitously on imaging, at times the features of 
these masses on imaging lend themselves to suggest a diagnosis (Table 1). The characteristics 
of adrenal tumors vary according to imaging modalities. Findings pertaining to specific imag-
ing modalities are discussed further below.
Adrenal size is one of the most important determinants of malignancy. Prior guidelines rec-
ommended adrenalectomy for patients with an adrenal mass ≥6 cm [4, 5]. However, in one of 
the largest multicenter retrospective studies, adrenal tumor size >4 cm provided the highest 
sensitivity (93%) in differentiating between benignity and malignancy [6]. The authors also 
showed that adrenocortical carcinoma (ACC) was more common in younger patients com-
pared to those patients with benign adenomas (median age 46 years versus 57 years). Due to 
the aggressive nature and rapid growth rate of ACC, and since achieving free margins is one 
of the most important determinants in extending patient survival [6, 7], current guidelines 
suggest adrenalectomy in all surgically fit patients with an adrenal mass >4 cm [8, 9].
2.1.1. Computed tomography
Specific tumor characteristics on computed tomography (CT) help differentiate benign from 
malignant adrenal tumors. The majority of benign adrenal adenomas has a high intracellular 
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Figure 1. Work-up algorithm of a solitary adrenal incidentaloma.
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lipid concentration and low density. Adrenal adenomas possess low attenuation on noncon-
trast CT represented by <10 hounsfield units (HU) (Figure 2). However, density alone is not 
an absolute predictor of malignancy. Approximately 30% of adenomas have low lipid content 
with attenuation >10 HU on noncontrast CT. In this situation, intravenous contrast enhance-
ment may be helpful. Benign adrenal adenomas usually have a density of 80–90 HU with IV 
contrast, and a >50% washout on delayed images.
On CT presentation, most ACC have irregular margins, irregular calcifications, and hetero-
geneous attenuation due to the presence of hemorrhage and necrosis. On contrast CT, ACC 
often demonstrates inhomogenous enhancement, a thin enhancing peripheral rim, attenua-
tion value >10 HU, and an absolute contrast washout <60% after 15 minutes of contrast admin-
istration [10]. ACC tend to be locally invasive, especially in vascular structures such as the 
adrenal and renal veins, and inferior vena cava. However, imaging alone cannot discriminate 
functioning from nonfunctioning adenomas. Although some radiographic findings may sug-
gest a diagnosis, functionality of adrenal tumors is made biochemically.
Adrenal masses Average size CT findings MRI findings
Lipid-rich adenoma <4 cm Well circumscribed, 
homogenous, <10 HU on 
unenhanced CT, >60% absolute 
contrast washout, >40% relative 
contrast washout
Homogenous intermediate T1 
signal intensity, low T2 signal 
intensity, loss of signal at out-
of-phase images
Lipid-poor adrenal adenoma <4 cm Well circumscribed, 
homogenous, >10 HU on 
unenhanced CT, >60% absolute 
contrast washout, >40% relative 
contrast washout
Homogenous, intermediate T1 
signal intensity, lack of signal 
loss at out-of-phase images
Adrenocortical carcinoma ≥4 cm Irregular, inhomogenous, >10 
HU on unenhanced CT, <60% 
absolute contrast washout, 
<40% relative contrast washout
Low T1 heterogeneous signal
High T2 signal intensity 
with nonenhancing necrotic 
components, lack of signal loss 
on out-of-phase images
Pheochromocytoma 2–5 cm Irregular, with calcifications, 
heterogeneous, > 10 HU 
on unenhanced CT, avid 
enhancement due to 
hypervascularity
Inhomogenous, low T1 signal 
intensity, high T2 signal 
intensity (“light bulb sign”), 
thick enhancing wall with 
central necrosis, calcifications, 
lack of signal loss on out-of-
phase images
Metastatic lesion Variable size Homogenous/heterogeneous 
based on size, irregular, >10 
HU, <60% absolute contrast 
washout, <40% relative contrast 
washout, increase in size on 
interval imaging, unilateral 
versus bilateral
Low T1 signal intensity, high T2 
signal intensity, heterogeneous 
enhancement, presence or lack 
of signal loss on out-of-phase 
images depending on presence 
of intracytoplasmic lipid
Table 1. Typical computed tomography (CT) scan and magnetic resonance imaging (MRI) findings for individual 
adrenal masses.
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On noncontrast CT, majority of pheochromocytomas are well-circumscribed, round-to-oval 
masses with peripheral calcifications. Size varies (average 5 cm), but due to presence of necro-
sis and/or hemorrhage, pheochromocytomas demonstrate heterogeneous attenuation. With 
contrast enhancement, pheochromocytomas display heterogeneous enhancement, density 
>100 HU, and retention of contrast on delayed imaging.
Other functioning adrenal tumors do not have specific CT characteristics that are definitive 
for diagnosis, but there are some general features that should be kept in mind. Cortisol-
secreting adrenal adenomas are usually small (average: 2–2.5 cm), and low-density lesions 
due to its high lipid concentration. Similarly, most aldosteronomas are <2 cm, solitary, and 
eccentric within the adrenal gland. However, the majority of patients with hyperaldosteron-
ism has bilateral hyperplasia and, therefore, require adrenal venous sampling to help identify 
a unilateral adenoma, even when finding a single adenoma on imaging.
Benign adrenal cysts are homogenous, nonenhancing lesions with attenuation near that of 
water (8 HU). Cysts may develop with or without wall calcifications, but the wall of the cyst 
is consistently <3 mm. Myelolipomas are rare benign tumors composed of bone marrow ele-
ments. These tumors vary in size, but measure on average 5 cm. Their radiographic appear-
ance depends on their histological composition, but the presence of local macroscopic fat is 
diagnostic in all cases (Figure 3). Fat-rich myelolipomas have unenhanced attenuation typi-
cally between −50 and −100 HU. They contain a pseudocapsule and about 20% have calcifica-
tions, especially when prior hemorrhage has occurred. Adrenal hematomas can be unilateral 
or bilateral, and typically have unenhanced attenuation values of 55–90 HU.
Figure 2. A 72-year-old female with 2.6 cm low-attenuating homogenous left adrenal mass (arrow) on noncontrast CT of 
the abdomen consistent for adrenal adenoma.
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2.1.2. Magnetic resonance imaging
Recent advances in technology that have made magnetic resonance imaging (MRI) promi-
nent in the imaging of adrenal tumors include gradient-echo breath-hold scans, chemical shift 
imaging with in-phase and out-of-phase T1-weighted sequences to detect intracellular lipid 
and water protons, as well as three-dimensional dynamic imaging.
Chemical shift MRI is based on differences in the frequencies the protons in water and fat 
display within a magnetic field. During in-phase imaging, the signals of water and fat protons 
are additive, whereas during out-of-phase imaging their signals are subtracted. Therefore, 
lipid-rich adenomas show loss of signal on out-of-phase imaging, while lipid-poor adenomas 
display modest signal loss. In equivocal cases, a relative drop in signal compared with the 
spleen establishes the presence of microscopic fat to help differentiate adenomas [11]. Benign 
adrenal adenomas are usually iso- or hypointense on T2 weighted images. Adenomas also 
present with early peak homogenous enhancement (usually within 52 seconds), which helps 
discriminate fat poor adenomas from malignant masses.
Pheochromocytoma has a typical appearance on MRI. These functional tumors usually pres-
ent with increased T2 signal intensity compared to adenomas, and in <50% of cases display 
the classic “light-bulb bright” T2 appearance (Figure 4). T2 hyperintensity is due to high fluid 
content and hypervascularity. In addition, the absence of microscopic fat results in absent 
signal loss between the in- and out-of-phase images. Adrenal masses with these findings are 
highly suggestive of pheochromocytoma, but lipid poor ACC or adrenal metastatic lesions 
may also have similar MRI characteristics.
Figure 3. A 55-year-old female with 7.7 cm fat—containing right adrenal mass (arrow) on noncontrast CT of the 
abdomen. Surgical pathology consistent for myelolipoma.
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As with CT scan, MRI cannot accurately differentiate functional adrenal masses. MRI shows 
similar sensitivity and specificity with CT in recognizing aldosteronomas. However, bilateral 
adrenal hyperplasia and unilateral aldosterone-producing adenomas show similar signal loss 
during out-of-phase sequences. Patients with adrenal Cushing’s syndrome will display MRI 
findings consistent for a lipid-rich adenoma. In some cases, indirect findings of a unilateral 
cortisol-producing adenoma include atrophy of the nonadenomatous contralateral adrenal 
gland due to suppressed stimulation from Adrenocorticotropic hormone (ACTH).
Some nonfunctioning adrenal masses have certain identifiable features on MRI. For instance, 
benign adrenal cysts appear as hypointense lesions on T1-weighted images and hyperintense 
lesions with a hypointense rim on T2-weighted images. The presence of macroscopic fat 
within myelolipomas yields a distinctive high T1 and moderate T2 signal intensity, with loss 
of signal of fat saturation in out-of-phase chemical shift sequences.
Adrenal hematoma has three distinct characteristics depending on their time of imaging. 
Acute (<7 days) adrenal hematoma will appear iso- or hypointense on T1-weighted images 
and markedly hypointense on T2-weighted images. Subacute (1 week to 2 months) hema-
toma will appear hyperintense on T1-weighted images. In the chronic stage (2–3 months), a 
T2-hypointense rim will appear along the periphery of the adrenal hematoma secondary to 
hemosiderin-laden macrophages.
For ACC, T1 sequences display a low heterogeneous signal, whereas on T2-weighted images, 
they appear hyperintense with nonenhancing necrotic components. Additionally, multipla-
nar MRI images allow identification of adrenal tissue when the tumor is invading into adja-
cent structures and the origin of the tumor cannot be distinguished.
Figure 4. A 62-year-old male with biochemically confirmed pheochromocytoma. MRI abdomen demonstrating 1.7 cm 
right adrenal mass (arrow) with markedly enhanced heterogeneous T2 signal typical of pheochromocytoma.
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2.1.3. Positron emission tomography (PET)
Normally functioning adrenal glands are usually not fluorodeoxyglucose (FDG) avid. FDG 
positron emission tomography (PET) allows the evaluation of primary lesions and metastases 
with excellent sensitivities. By definition, an adrenal mass found during cancer surveillance 
or staging does not constitute an adrenal incidentaloma. However, adrenal masses can be 
found incidentally in PET scan conducted for other reasons besides cancer surveillance or 
staging.
The evaluation of adrenal glands with FDG PET usually originates from its use in lung cancer 
staging. An adrenal lesion is considered malignant if it typically displays higher Standardized 
Uptake Values (SUV) values than the liver (1.5). However, a recent study reported 99% sensi-
tivity and 92% specificity of PET CT in differentiating benign from malignant adrenal lesions 
when a cut-off value of SUV
max
 of 3.1 was used. According to recent meta-analysis, mean sensi-
tivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio 
values for differentiating between benign and malignant adrenal disease were 0.97 (95% CI: 0.93, 
0.98), 0.91 (95% CI: 0.87, 0.94), 11.1 (95% CI: 7.5, 16.3), 0.04 (95% CI: 0.02, 0.08), and 294 (95% CI: 
107, 805), respectively [12]. Another study showed 100% sensitivity and 88% specificity in dis-
tinguishing ACC from adrenal adenoma, when a cut-off value of above 1.45 for adrenal-to-liver 
SUV 
max
 ratio was used [13]. False-positive results, however, may arise in patients with pheo-
chromocytoma, adrenal hyperplasia, and functioning adenomas (5%).
Currently, routine use of PET CT in the evaluation of adrenal incidentalomas has not been 
validated, and it is primarily used in patients with prior history of malignancy with nondiag-
nostic findings on CT scan.
2.2. Presentation and biochemical testing of functional adrenal tumors
Hormonal evaluation of adrenal incidentalomas is paramount for proper evaluation and 
diagnosis. Despite advances in imaging technology, no radiographic finding can definitively 
establish a diagnosis without biochemical testing. In this section, the appropriate biochemical 
testing for an adrenal incidentaloma is described.
2.2.1. Hypercortisolism
The most common cause of hypercortisolism is exogenous glucocorticoid use. Of the endog-
enous causes, most affected individuals (75%) will have Cushing’s disease caused by an ACTH-
secreting pituitary adenoma. The remainder is composed of cortisol-secreting adrenal adenomas 
(15%) and ectopic ACTH syndrome (<10%), usually caused by neuroendocrine tumors or bron-
chogenic malignant neoplasms arising in the thoracic cavity. Patients with hypercortisolism 
present with a variety of signs and manifestations; however, those subset of patients with adre-
nal incidentalomas are rarely symptomatic. Signs and symptoms of adrenal Cushing’s syn-
drome include central obesity, moon facies, purple striae, hypertension, easy bruising, plethora, 
hirsutism, muscle weakness, glucose intolerance or diabetes, osteopenia, menstrual irregulari-
ties, and emotional disturbances. More commonly, patients with adrenal incidentalomas pres-
ent as subclinical Cushing syndrome, with no findings suggestive of hypercortisolism.
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Three screening tests are commonly used to make the diagnosis of hypercortisolism and are 
based on several pathophysiological derangements. First, excess cortisol secretion can be 
detected by an elevated 24 hours urine-free cortisol with the diagnosis made when cortisol 
is four times the normal value. Loss of normal diurnal cortisol variation is best detected by 
testing late-night salivary cortisol between 11 pm and midnight, and a value >2.0 ng/mL is 
diagnostic. Second, loss of negative feedback is best detected with a low-dose dexametha-
sone suppression test where 1 mg of dexamethasone is given at 11 pm and serum cortisol is 
tested at 8 am the next morning. Suppression of cortisol level <1.8 μg/dL has the best negative 
predictive value for Cushing’s disease. Diagnosis of subclinical Cushing’s syndrome is con-
firmed with a serum cortisol level ≥5.0 μg/dL after a 1 mg dexamethasone suppression test 
[9]. Finally, after diagnosis has been established, ACTH levels will further determine if the 
cause of hypercortisolism originates in the pituitary or adrenal glands. Undetectable ACTH 
levels are consistent with adrenal origin. In patients with high ACTH levels, a combination 
of brain MRI, high-dose dexamethasone suppression test, and bilateral petrosal sinus ACTH 
sampling will determine the origin of ACTH production and further guide  appropriate 
treatment.
2.2.2. Pheochromocytoma
Pheochromocytoma refers to a tumor of catecholamine producing cells, the majority of which 
arise in the adrenal medulla and affects about 0.2% of hypertensive individuals. A small per-
centage (1–2%), known as paragangliomas, arise from chromaffin-producing neural crest cells 
that parallel the sympathetic and parasympathetic ganglia. These locations include the para-
aortic sympathetic chain, the sympathetic and parasympathetic chain of the neck, posterior 
mediastinum, and the organ of Zuckerkandl. The hallmark of pheochromocytoma is persistent 
hypertension with episodic headaches, sweating, and tachycardia. Other common symptoms 
of this disease include palpitations, orthostatic hypotension, heart disease, pallor, nausea, 
anxiety, and flushing. Approximately 10% of patients, however, remain asymptomatic.
Most pheochromocytomas secrete norepinephrine, epinephrine, and rarely dopamine. 
Traditionally, diagnosis was based on 24 hours measurement of urine catecholamines and 
metanephrines. Plasma-free metanephrines are produced continuously through metabolism 
of catecholamines within pheochromocytoma tumor cells, in contrast to episodic secretion of 
catecholamines [14]. Plasma metanephrine levels exceeding 3–4 times normal are highly diag-
nostic for pheochromocytoma (normal value <0.5 nmol/L). Given the rarity of pheochromocy-
tomas, and 86% specificity observed with plasma-free metanephrine tests, confirmation needs 
to be established with measurement of 24 hours urine metanephrines and catecholamines. In 
equivocal cases, clonidine suppression test may be obtained, which measures plasma-free 
metanephrines after oral administration of 0.3 mg of clonidine. It is important to discontinue 
medications such as phenoxybenzamine, sympathomimetics, acetaminophen, and tricyclic 
antidepressants prior to any biochemical testing due to interference with the results.
Patients with concerns for metastatic disease due to large size of primary tumor or extra-
adrenal, multifocal, or suspected genetic components, should undergo 123I meta-iodoben-
zylguanidine (MIBG) scintigraphy. PET CT is the preferred imaging modality over MIBG 
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scan in patients with metastatic disease. Up to 25% of pheochromocytomas occur in the 
setting of hereditary syndrome, such as multiple endocrine neoplasia types 2A and B, von 
Hippel-Lindau disease, neurofibromatosis type 1, and hereditary paraganglioma syndrome. 
Therefore, genetic testing needs to be obtained in a subset of patients less than 50 years, with 
bilateral or multifocal disease or malignant extra-adrenal disease.
2.2.3. Primary hyperaldosteronism
Primary hyperaldosteronism (Conn’s syndrome) is the most common cause of secondary 
hypertension, and it refers to a group of disorders in which aldosterone production by the 
zona glomerulosa is inappropriately high, relatively autonomous, and independent of the 
renin-angiotensin system. The most common cause of primary hyperaldosteronism is bilat-
eral adrenal hyperplasia (60%), followed by functional unilateral adenoma (35%), unilateral 
adrenal hyperplasia (2%), and rarely functional adrenocortical carcinoma (1%), ectopic aldo-
sterone producing tumor (1%), and familiar hyperaldosteronism (1%).
Most patients with primary hyperaldosteronism are asymptomatic, but all have hyperten-
sion. Hypertension associated with Conn’s syndrome is unique in that it is not only persistent 
but also progressive and difficult to control. Patients with primary hyperaldosteronism usu-
ally require multiple hypertensive medications, often are taking more than three. Patients 
with an adrenal incidentaloma without hypertension do not have Conn’s syndrome, and do 
not need to undergo biochemical testing for primary hyperaldosteronism. Furthermore, the 
pathognomonic finding of hypertension and hypokalemia is highly suggestive of Conn’s syn-
drome, but only 30% present in this manner. Symptoms associated with hypokalemia are 
muscle weakness, polyuria, polydipsia, nocturia due to nephrogenic diabetes insipidus, par-
esthesias, and, rarely, tetany.
The most reliable screening method for primary hyperaldosteronism is the ratio of plasma 
aldosterone concentration (PAC) to plasma renin activity (PRA). Screening should be per-
formed by taking a random morning PAC and PRA value after correction of hypokalemia 
due to interference with aldosterone secretion. Aldosterone receptor antagonists spironolac-
tone and eplerenone, as well as high-dose amiloride, are the only medications that absolutely 
affect the interpretation of the PAC:PRA ratio, and these medications should be discontinued 
5–6 weeks before the screening test. A PAC:PRA ratio ≥20 along with a PAC value ≥15 ng/
ml is considered a positive test for primary aldosteronism. Given the negative feedback on 
renin, PRA is suppressed in Conn’s syndrome, and an elevated PRA excludes the diagnosis. 
A confirmation salt loading test may be performed following a positive screening test, or in 
patients with equivocal results. Typically, a three-day oral salt loading test (>200 mEq/day) is 
performed and 24 hours urine aldosterone excretion is measured. A urine aldosterone excre-
tion ≥12 μg/24 hours confirms primary hyperaldosteronism. Alternatively, PAC is measured 
after intravenous infusion of 2 L of normal saline over 4 hours. A PAC value ≥10 ng/dL sup-
ports the diagnosis.
Following biochemical diagnosis of primary hyperaldosteronism, adrenal venous sampling 
(AVS) should be performed to differentiate unilateral adenoma from bilateral hyperplasia. 
All patients found to have an adrenal mass <1 cm require AVS. Unfortunately, there is a lack 
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of standardized protocols, and therefore, the procedure as well as interpretation of results 
can vary between medical centers [15]. AVS requires sampling of bilateral adrenal veins and 
peripheral (inferior vena cava) locations for aldosterone and cortisol. Cortisol is utilized to 
confirm successful cannulation of the adrenal veins. A more than fivefold elevation of the 
cortisol concentration in the adrenal vein sample relative to peripheral blood is confirmatory, 
and it is referred as the selectivity index. The side of aldosterone secretion is determined by 
the lateralization index that compares the aldosterone to cortisol ratios of the dominant to 
nondominant side. A ratio greater than 4:1 confirms unilateral adenoma and surgery should 
be considered. Some centers advocate the use of cosyntropin (either as continuous or bolus 
infusion) when performing AVS, especially when baseline successful cannulation rates are 
low. One study found a significant increase in the selectivity index after ACTH infusion; 
however, no effects were observed on the lateralization index [16]. Overall, when performed 
correctly, adrenal vein sampling has a sensitivity of 95% and specificity of 100% in detecting 
unilateral autonomous aldosterone secretion.
2.2.4. Adrenocortical carcinoma
Adrenocortical carcinoma (ACC) is a rare tumor and carries poor prognosis. At time of diag-
nosis, the majority are very large in size (mean size 9–13 cm), extend beyond the adrenal 
gland and metastatic. About two-thirds of all ACC are hormonally active and manifest with 
hypercortisolism and virilization and rarely hyperaldosteronism and feminization. About 
20% of ACC will display virilization, whereas about one-fourth of cases will present with a 
mixed picture of Cushing’s syndrome and virilization. However, when discovered as adrenal 
incidentalomas, they tend to be clinically biochemical inactive. Some patients may present 
with flank pain, abdominal discomfort, or fever due to hemorrhage within the tumor. All 
patients with radiographically suspected ACC, even when asymptomatic, should undergo 
biochemical evaluation for Cushing’s syndrome, hyperaldosteronism, and be tested for sex 
steroids and its precursors (androstenedione, testosterone, dehydroepiandrosterone sulfate, 
and 17β-estradiol in postmenopausal women and men only). Identification of biochemical 
markers does not only aid in the perioperative management, but hormonal markers serve as 
tumor markers during postoperative surveillance.
2.2.5. Other rare tumors (sex steroid-producing tumors)
Sex steroid-producing tumors are rare. Most of these tumors are virilizing and may manifest 
at a late stage in association with an advanced ACC. Almost all feminizing tumors are malig-
nant, whereas one-third of virilizing tumors are malignant.
2.3. Surgical indications and preoperative preparation
2.3.1. Hypercortisolism
Patients with unilateral cortisol-producing adenoma will have resolution of symptoms in 
about 90% of cases when treated surgically. Resolution of symptoms may take months to 
years to occur. Certain clinical manifestations, such as bone density, body composition, and 
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inflammation may be persistent. Given the progressive negative systemic effect of hypercorti-
solism, patients with Cushing’s syndrome should undergo adrenalectomy. Studies have also 
shown that patients with subclinical Cushing’s syndrome may also benefit from adrenalec-
tomy. A randomized study comparing adrenalectomy over medical management in patients 
with subclinical Cushing’s syndrome showed that in the surgical group, diabetes mellitus 
normalized or improved in 63% of patients, hypertension in 67%, hyperlipidaemia in 38%, 
and obesity in 50%, whereas some patients in the medical group showed worsening of those 
parameters [17].
Patients with unilateral adrenal Cushing’s syndrome will have chronic hypothalamic-pitu-
itary-adrenal (HPA) axis suppression. As a result, the contralateral adrenal gland displays 
atrophy that is resistant to ACTH stimulation. Therefore, perioperative and postoperative 
corticosteroids need to be administered. Glucocorticoid administration needs to be continued 
on average 6–18 months until the HPA axis has completely recovered.
2.3.2. Pheochromocytoma
All patients with pheochromocytomas should undergo surgical resection. Laparoscopic adre-
nalectomy is commonly the treatment of choice. Tumors that suggest malignancy, such as 
large lesions, or those with evidence of local tumor invasion, should be resected with an open 
approach to avoid capsule disruption or tumor seeding. Cortical-sparing adrenalectomy is 
recommended in patients with hereditary pheochromocytoma, with small tumors and prior 
history of contralateral adrenalectomy in order to prevent permanent adrenal insufficiency.
After pheochromocytoma localization by imaging, all patients need to be started on α-blocker 
to counteract the sympathetic effects of catecholamine-producing cells. Goal of medical treat-
ment should aim at reversing the downregulation of α-adrenergic receptors, and therefore, 
prevent intraoperative hemodynamic instability after tumor removal. Treatment should be 
initiated for at least 2 weeks preoperatively with the goal of eliciting orthostatic hypotension. 
The most frequently used alpha agent is phenoxybenzamine, which constitutes a nonselec-
tive, irreversible α1 agent with the longest half-life. Medical treatment is started at 10 mg twice 
daily, and titrated up to 300–400 mg daily until the patient becomes normotensive or develops 
intolerable side effects. Alternative agents include prazosin and terazosin. β-blockers, prefer-
ably propranolol, should be added in patients who develop persistent tachycardia or arrhyth-
mias when α-blockade is initiated.
Intraoperatively, close communication between surgeon and anesthesiologist is essential. 
Invasive monitoring is mandated, and α and β-blocking agents as well as vasopressors need 
to be readily available. Excessive surgical manipulation of the tumor should be avoided, as it 
can stimulate further catecholamine secretion. Postoperatively, all patients need to be closely 
monitored for hypotension and hypoglycemia. Antihypertensive agents, with the exception 
of β-blockers, should be withheld and only used in patients with underlying essential hyper-
tension. Patients with incomplete tumor removal or known metastatic disease should con-
tinue the use of α-blockers. Postoperatively, all patients need lifelong yearly follow-up for 
risk of recurrence.
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2.3.3. Primary hyperaldosteronism
Patients with a unilateral aldosterone-producing adenoma commonly undergo laparoscopic 
adrenalectomy. Excess plasma aldosterone levels are deleterious, even when hyperten-
sion and hypokalemia are adequately controlled. Long-term sequelae of aldosterone excess 
include myocardial fibrosis, left ventricular hypertrophy, congestive heart failure, myocardial 
infarction, and stroke. Reductions in blood pressure and number of antihypertensive medica-
tions, as well as plasma and urine aldosterone levels can be observed as soon as 24 hours after 
successful surgery. Hypokalemia will resolve in all cases, whereas more than 80% of patients 
will show significant improvement of hypertension. Between 30 and 60% of patients will be 
completely weaned off antihypertensive medications, especially the young population with 
a short clinical course.
The following subset of patients show reduced benefit from adrenalectomy and will continue 
to require antihypertensive medications postoperatively: patients with a prolonged clinical 
course, men >45 years old, patients nonresponsive to spironolactone, need for more than two 
antihypertensive medications, and positive family history of hypertension. Patients with a 
delay in diagnosis often have irreversible secondary cardiovascular and renal changes render-
ing adrenalectomy less effective.
2.3.4. Adrenocortical carcinoma
Patients with radiographically suspected ACC who are surgically fit should undergo open 
adrenalectomy. The following concerning CT features indicate malignancy: unenhanced 
attenuation >10 HU, tumor >4 cm, irregular margins, nonhomogenous contrast enhance-
ment, or local invasion to adjacent structures, especially the inferior vena cava. In cases of 
local invasion of adjacent structures, en bloc resection of the adrenal gland with the involved 
organ should be performed. Capsule disruption should be avoided, since it increases local 
recurrence. Traditionally, if ACC was recognized intraoperatively, conversion to an open pro-
cedure was mandated, since the laparoscopic approach had been linked to increased local 
recurrence, tumor seeding at port sites, and peritoneal spread. A recent study, however, has 
shown no difference in long-term oncological outcomes in carefully selected patients with 
stage I/II ACC, tumors <10 cm, and no evidence of extra-adrenal invasion, who underwent 
laparoscopic adrenalectomy by experienced surgeons [18].
2.4. Follow-up for nonoperative patients
Patients with adrenal incidentalomas who do not fulfill criteria for surgical resection should 
undergo repeat imaging at 3–6 months, and then annually, for 1–2 years. In addition, hor-
monal evaluation should be obtained annually for 5 years. The risk of enlargement during 1, 
2, and 5 years is 6, 14, and 29%, respectively, and the risk of the mass becoming hormonally 
active during the same periods is 17, 29, and 47%, respectively. The most common hormon-
ally active lesion in patients with previously inactive adenomas is subclinical Cushing’s syn-
drome. Indications for surgical resection during follow-up include conversion to functional 
tumor and enlargement over 1 cm during follow-up imaging.




The majority of adrenal incidentalomas represent nonfunctioning adenomas. Unique imaging 
features of an adrenal mass, along with appropriate history and biochemical evaluation, can 
help determine the underlying diagnosis for adrenal incidentalomas and guide further treat-
ment. Patients who do not fulfill surgical criteria should undergo repeat imaging as well as 
biochemical evaluation and expectant management.
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